Cord blood prolactin and thyroid hormone levels after antenatal administration of betamethasone or ambroxol for prevention of respiratory distress syndrome (RDS).
Several studies showed that ambroxol is efficacious in enhancing fetal lung maturation, provided large doses are given. We investigated cord blood levels of PRL and thyroid hormones in 31 infants born after antenatal administration of betamethasone, in 31 infants born to mothers treated with ambroxol for prevention of RDS and in 27 infants whose mothers had not received any drug enhancing fetal lung maturity. The only significant difference (p less than 0.05) between the groups was noted in T3 mean levels that were higher in the ambroxol group than in the betamethasone group between the 33th to 36th week of gestation. Hormone levels did not appear significantly different in infants who developed RDS rather than in infants who did not.
D000551:Ambroxol / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use*; D001964:Bromhexine / Q000031:analogs & derivatives*; D005260:Female; D005312:Fetal Blood / Q000032:analysis*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control*; D013974:Thyroxine / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood*
D014284:Triiodothyronine; D000551:Ambroxol; D011388:Prolactin; D001623:Betamethasone; D001964:Bromhexine; D013974:Thyroxine